Case Brennan
Appearances
- DateMay 18, 2024Esophageal adenocarcinoma (EAC) has had a rising incidence in the US, prompting guidelines for endoscopic screening in those with risk factors for its precursor Barret’s esophagus (BE)…
Presenter
Speakers
University of California, Los AngelesUniversity of Kansas School of Medicine and Kansas City VA Medical CenterWashington University School of MedicineWashington University in St. LouisUniversity of Colorado School of MedicineUniversity of ColoradoUCLANorthwestern University - DateMay 18, 2024Recent studies have described the durability of EET for BE-related neoplasia and the risk of neoplastic recurrence after achieving complete eradication of intestinal metaplasia (CE-IM). Current guidelines for endoscopic surveillance intervals post-EET are based on limited evidence…
Presenter
Johns Hopkins HospitalSpeakers
Washington University in St. LouisUniversity of Colorado School of MedicineUniversity of North Carolina at Chapel Hill School of MedicineMayo ClinicNorthwestern UniversityWashington University School of MedicineUniversity of California, Los AngelesUniversity of North CarolinaUCLAUniversity of Colorado - DateMay 19, 2024INTRODUCTION: EET is endorsed by guidelines for treatment of BE-related neoplasia patients. Few studies describe long-term durability outcomes in BE patients who achieve complete eradication of intestinal metaplasia (CE-IM) following EET…
Presenter
Speakers
University of California, Los AngelesUCLAUniversity of Kansas School of Medicine and Kansas City VA Medical CenterWashington University School of MedicineWashington University in St. LouisUniversity of Colorado School of MedicineNorthwestern UniversityUniversity of Colorado